Dr. Zhen Wang, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 251
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
GA license 103708 -
Hematology & Oncology Physician
NY license 303988
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Piedmont Hospital, Inc Atlanta, GA
- Piedmont Henry Hospital Stockbridge, GA
- Piedmont Mountainside Hospital Inc Jasper, GA
- Piedmont Cartersville Medical Center Cartersville, GA
Medical groups
- Piedmont Providers LLC (530 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 251
- Services billed
- 1,439
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 243 | 84 |
| Insertion of needle into vein for collection of blood sample | 213 | 114 |
| Established patient office or other outpatient visit, 40-54 minutes | 199 | 75 |
| Established patient office or other outpatient visit, 30-39 minutes | 198 | 102 |
| Established patient office or other outpatient visit, 20-29 minutes | 94 | 65 |
| New patient office or other outpatient visit, 60-74 minutes | 48 | 48 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 35 | 35 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 26 | 23 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 17 | 14 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Atlanta, GA | 162 |
| Ondansetron Hcl Other prescribers in Atlanta, GA | 103 |
| Prochlorperazine Maleate Other prescribers in Atlanta, GA | 88 |
| Loperamide (loperamide hcl) Other prescribers in Atlanta, GA | 79 |
| Prednisone Other prescribers in Atlanta, GA | 39 |
| Gabapentin Other prescribers in Atlanta, GA | 38 |
| Eliquis (apixaban) Other prescribers in Atlanta, GA | 33 |
| Xarelto (rivaroxaban) Other prescribers in Atlanta, GA | 33 |
| Mirtazapine Other prescribers in Atlanta, GA | 30 |
| Hydroxyurea Other prescribers in Atlanta, GA | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 61 payments worth $1,537 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $347 |
|---|---|
| Pfizer Inc. | $127 |
| Regeneron Healthcare Solutions, Inc. | $81.60 |
| Daiichi Sankyo Inc. | $80.18 |
| Invivyd Inc | $63.03 |
| Genzyme Corporation | $62.57 |
| Merck Sharp & Dohme LLC | $62.53 |
| Celgene Corporation | $49.92 |
| Food and Beverage | $1,468 |
|---|---|
| Education | $68.49 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Education IMFINZI · Oncology · in-kind Company’s descriptionJournal Article | $68.49 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $7,295 in research payments for these studies, mostly to the institutions running them.
- EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma
Novocure Inc. - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
AbbVie Inc. · Active, not recruiting · NCT04401748
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.